Farxiga and Simvastatin Interaction: Can You Take Dapagliflozin with a Statin?

Why These Two Drugs End Up in the Same Pill Organizer

Most adults prescribed dapagliflozin for type 2 diabetes (T2D), heart failure (HF), or chronic kidney disease (CKD) already carry at least one cardiovascular risk factor that calls for statin therapy. The overlap is not coincidental. It reflects guideline-concordant care.

The American Diabetes Association (ADA) 2024 Standards of Care recommend moderate- to high-intensity statin therapy for nearly all adults with T2D aged 40 to 75 [1]. Separately, the same guidelines recommend SGLT2 inhibitors like dapagliflozin for patients with T2D who have established atherosclerotic cardiovascular disease (ASCVD), HF, or CKD [1]. A patient who meets both criteria will be prescribed both drugs. In DECLARE-TIMI 58, the landmark cardiovascular outcomes trial for dapagliflozin (N=17,160), roughly 75% of enrollees were already taking a statin at randomization [2]. The combination is not a niche scenario. It is the default.

Given simvastatin's well-known CYP3A4 vulnerability to drug interactions (grapefruit juice, azole antifungals, macrolide antibiotics, and certain calcium-channel blockers can all raise simvastatin exposure and rhabdomyolysis risk [3]), the question of whether dapagliflozin adds to that risk is clinically reasonable. The short answer: it does not.

Metabolism Pathways Do Not Cross

Dapagliflozin is cleared primarily through UGT1A9-mediated glucuronidation in the liver and kidney, producing the inactive metabolite dapagliflozin 3-O-glucuronide [4]. CYP enzymes play a minor role. The Farxiga prescribing information states that CYP-mediated metabolism is "a minor clearance pathway" for dapagliflozin [4].

Simvastatin, by contrast, is a lactone prodrug that undergoes CYP3A4-dependent oxidative metabolism to its active beta-hydroxy acid form [3]. Drugs that inhibit or compete for CYP3A4 can sharply increase simvastatin plasma concentrations. The FDA label for simvastatin specifically warns against co-administration with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, erythromycin, and HIV protease inhibitors [3].

Dapagliflozin is not a CYP3A4 inhibitor or inducer. The Farxiga label confirms that in vitro studies showed "no inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or induction of CYP1A2, CYP2B6, or CYP3A4" [4]. Because dapagliflozin neither blocks nor accelerates CYP3A4 activity, it cannot raise or lower simvastatin levels.

The reverse direction is also clean. Simvastatin does not inhibit UGT1A9 at clinically relevant concentrations, so it will not impair dapagliflozin glucuronidation. No P-glycoprotein (P-gp) interaction of clinical significance has been identified between the two agents either [4].

What the Phase III Data Show

Large-scale randomized trials provide the strongest evidence that this combination is safe. None of these trials excluded patients on statins, and none reported an excess of statin-related muscle toxicity in the dapagliflozin arm.

DECLARE-TIMI 58 randomized 17,160 patients with T2D and either established ASCVD or multiple risk factors to dapagliflozin 10 mg or placebo, with a median follow-up of 4.2 years [2]. Approximately three-quarters of participants were on background statin therapy. The trial found that dapagliflozin reduced hospitalization for heart failure (HR 0.73; 95% CI 0.61 to 0.88) without increasing serious adverse events, including musculoskeletal events, compared with placebo [2].

DAPA-HF enrolled 4,744 patients with HF and reduced ejection fraction (HFrEF), both with and without diabetes, and randomized them to dapagliflozin 10 mg or placebo [5]. Statin use at baseline was around 56%. The primary composite endpoint (worsening HF or cardiovascular death) was reduced by 26% (HR 0.74; 95% CI 0.65 to 0.85) [5]. The safety profile in the dapagliflozin group was consistent with placebo, and no myopathy signal was detected.

DAPA-CKD enrolled 4,304 patients with CKD (eGFR 25 to 75 mL/min/1.73 m²) and randomized them to dapagliflozin 10 mg or placebo [6]. The trial was stopped early for efficacy. Adverse event rates, including muscle-related complaints, were balanced between groups [6].

Across these three trials alone, more than 26,000 patients were randomized, and a substantial proportion received concurrent statin therapy. The cumulative safety dataset gives no signal that dapagliflozin worsens statin tolerability.

Pharmacokinetic Interaction Studies

AstraZeneca conducted formal drug interaction studies during dapagliflozin development. While simvastatin specifically was not a standalone interaction study drug, the company tested dapagliflozin against other CYP3A4-relevant agents.

In a study with valsartan (which shares some hepatic clearance pathways), co-administration did not change dapagliflozin AUC or Cmax to a clinically relevant degree [4]. A dedicated interaction study with pioglitazone (a CYP2C8 substrate with minor CYP3A4 involvement) showed no meaningful pharmacokinetic changes [4].

The European Medicines Agency (EMA) assessment report for dapagliflozin concluded that "the risk for clinically relevant drug-drug interactions with dapagliflozin is considered low" based on in vitro enzyme and transporter data as well as in vivo interaction studies [7]. The 2020 European Society of Cardiology (ESC) guidelines on diabetes and cardiovascular disease list SGLT2 inhibitors as having a "favorable drug interaction profile" compared with many older glucose-lowering agents [8].

Simvastatin's Real Drug Interaction Risks

While dapagliflozin is not a concern, simvastatin does carry genuine interaction risks that prescribers should monitor. The FDA limits the simvastatin dose to 20 mg daily when combined with amiodarone, amlodipine, or ranolazine, and to 10 mg daily with verapamil or diltiazem [3]. Simvastatin is contraindicated with strong CYP3A4 inhibitors, gemfibrozil, cyclosporine, and danazol [3].

Dr. Robert Rosenson, a lipid specialist at the Icahn School of Medicine at Mount Sinai, has noted: "Simvastatin's CYP3A4 dependence makes it one of the more interaction-prone statins. When adding new medications, clinicians should check specifically for CYP3A4 interference, but SGLT2 inhibitors are not among the offending drug classes" [9].

For patients on complex regimens, switching from simvastatin to a statin with lower interaction potential (rosuvastatin or pitavastatin, neither of which depends on CYP3A4) may reduce future polypharmacy risk, though this decision is separate from dapagliflozin prescribing [3].

Pharmacodynamic Considerations

Beyond pharmacokinetics, there is a pharmacodynamic angle worth noting. Both dapagliflozin and simvastatin can affect renal function and electrolytes, though through different mechanisms.

Dapagliflozin causes an initial dip in eGFR of approximately 3 to 5 mL/min/1.73 m² in the first two weeks of treatment, reflecting reduced glomerular hyperfiltration rather than kidney injury [6]. This change stabilizes and is associated with long-term renal protection. Simvastatin has been associated with mild, dose-related proteinuria in some analyses, though this is considered a tubular effect rather than glomerular damage [10].

Neither drug significantly alters the other's effect on the kidney. The DAPA-CKD subgroup analyses showed consistent renal benefit regardless of background lipid-lowering therapy [6].

On glycemic effects, dapagliflozin lowers HbA1c by approximately 0.5 to 0.8 percentage points through glucose excretion [4]. Statins, particularly high-intensity ones, carry a small but real risk of increasing fasting glucose. A meta-analysis of 13 statin trials (N=91,140) found a 9% relative increase in diabetes incidence with statin therapy [11]. These effects run in opposite metabolic directions but do not constitute a pharmacodynamic interaction. They are independent drug effects that should each be monitored on their own terms.

Monitoring When Taking Both Drugs

No special monitoring beyond standard-of-care is required for the dapagliflozin-simvastatin combination. The 2018 AHA/ACC cholesterol guideline recommends checking a fasting lipid panel 4 to 12 weeks after starting a statin and then every 3 to 12 months [12].

For dapagliflozin, the ADA recommends monitoring serum creatinine, eGFR, and potassium within one to two weeks of initiation, and periodically thereafter [1]. Patients should be counseled about symptoms of genital mycotic infections and, rarely, euglycemic diabetic ketoacidosis (DKA), especially around surgery or fasting.

Regarding statin safety, patients should report unexplained muscle pain, tenderness, or weakness. A creatine kinase (CK) level is appropriate if symptoms develop but is not required at routine visits. If a patient develops myalgias while on both drugs, dapagliflozin is unlikely to be a contributing factor. The prescriber should instead evaluate for known simvastatin interaction culprits: new antibiotics, antifungals, calcium-channel blockers, or high grapefruit consumption [3].

The 2019 ESC/EAS guidelines for the management of dyslipidemias emphasize that "in the case of statin-associated muscle symptoms, reversible causes (hypothyroidism, drug interactions, excess physical exertion) should be excluded before attributing symptoms to the statin itself" [13].

When to Involve a Pharmacist

A pharmacy consultation is reasonable in three specific situations involving this combination.

First, if the patient is on simvastatin 80 mg daily. The FDA restricts this dose to patients who have been stable on it for 12 months or more without muscle toxicity [3]. Adding any new medication to a simvastatin 80 mg regimen warrants a fresh interaction check, even though dapagliflozin itself is not the risk.

Second, if the patient takes five or more concurrent medications. Polypharmacy multiplies the chance that one of the other drugs will interact with simvastatin via CYP3A4. A pharmacist can run a comprehensive interaction screen.

Third, if the patient has an eGFR below 30 mL/min/1.73 m². Dapagliflozin's glucose-lowering effect is reduced at very low eGFR, though renal and cardiac benefits persist. Simvastatin does not require renal dose adjustment, but overall drug clearance changes in advanced CKD can affect statin exposure [3][6].

What About Other SGLT2 Inhibitors and Statins?

The metabolic profile of the SGLT2 inhibitor class is consistent on this question. Empagliflozin (Jardiance) is also metabolized primarily by UGT enzymes (UGT1A3, UGT1A8, UGT1A9, UGT2B7) and does not inhibit or induce CYP3A4 [14]. Canagliflozin (Invokana) is metabolized by UGT1A9 and UGT2B4 and similarly lacks CYP3A4 effects [15].

No SGLT2 inhibitor approved in the United States has a labeled interaction with any statin. This is a class-wide characteristic driven by the shared reliance on UGT-mediated glucuronidation rather than CYP oxidation. Patients who switch between SGLT2 inhibitors do not need statin dose changes.